Skip to main content

Table 1 Demography and clinical characteristics of patients (n = 8)

From: A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer

Characteristics

Number

Percent

Age

 

 Median (range)

49.2 (35.7–71.8)

Histology Type

  

 Invasive Ductal Carcinoma

8

100

Hormone Receptor Status

  

 ER- and PR-

3

37.5

 ER- and PR+

4

50.0

 ER+ and PR-

0

0

 ER+ and PR+

1

12.5

HER2 Expression

  

 IHC 0-2+ and/or FISH -

3

37.5

 IHC 2+ and FISH +, IHC 3+

5

62.5

Hormonal and HER2 Status

  

 Triple Negative

0

0.0

 ER+ and HER2-

3

37.5

 HER2+

5

62.5

Molecular Subtype

  

 Luminal A

3

37.5

 Luminal B

1

12.5

 HER2+/ER-

4

50.0

 Basal-like

0

0.0

ECOG Performance Status

  

 0-1

4

50.0

 2

3

37.5

 3

1

12.5

  1. Note: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, FISH fluorescent in situ hybridization, ECOG Eastern Cooperative Oncology Group